Usage Information

Cancer epigenetics drug discovery and development: the challenge of hitting the mark
Robert M. Campbell, Peter J. Tummino
Robert M. Campbell, Peter J. Tummino
Published January 2, 2014
Citation Information: J Clin Invest. 2014;124(1):64-69. https://doi.org/10.1172/JCI71605.
View: Text | PDF | Corrigendum
Review Series

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

Abstract

Over the past several years, there has been rapidly expanding evidence of epigenetic dysregulation in cancer, in which histone and DNA modification play a critical role in tumor growth and survival. These findings have gained the attention of the drug discovery and development community, and offer the potential for a second generation of cancer epigenetic agents for patients following the approved “first generation” of DNA methylation (e.g., Dacogen, Vidaza) and broad-spectrum HDAC inhibitors (e.g., Vorinostat, Romidepsin). This Review provides an analysis of prospects for discovery and development of novel cancer agents that target epigenetic proteins. We will examine key examples of epigenetic dysregulation in tumors as well as challenges to epigenetic drug discovery with emerging biology and novel classes of drug targets. We will also highlight recent successes in cancer epigenetics drug discovery and consider important factors for clinical success in this burgeoning area.

Authors

Robert M. Campbell, Peter J. Tummino

×

Usage data is cumulative from February 2024 through February 2025.

Usage JCI PMC
Text version 747 54
PDF 92 30
Figure 108 7
Table 47 0
Citation downloads 66 0
Totals 1,060 91
Total Views 1,151
(Click and drag on plot area to zoom in. Click legend items above to toggle)

Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.

Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.

Advertisement